BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 2391071)

  • 1. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration.
    Nakagawa M; Colombo C; Setchell KD
    Hepatology; 1990 Aug; 12(2):322-34. PubMed ID: 2391071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis.
    Colombo C; Setchell KD; Podda M; Crosignani A; Roda A; Curcio L; Ronchi M; Giunta A
    J Pediatr; 1990 Sep; 117(3):482-9. PubMed ID: 2391610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study.
    Colombo C; Crosignani A; Assaisso M; Battezzati PM; Podda M; Giunta A; Zimmer-Nechemias L; Setchell KD
    Hepatology; 1992 Oct; 16(4):924-30. PubMed ID: 1398498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bile acid conjugation in early stage cholestatic liver disease before and during treatment with ursodeoxycholic acid.
    Fracchia M; Setchell KD; Crosignani A; Podda M; O'Connell N; Ferraris R; Hofmann AF; Galatola G
    Clin Chim Acta; 1996 Apr; 248(2):175-85. PubMed ID: 8740581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease.
    Lindblad A; Glaumann H; Strandvik B
    Hepatology; 1998 Jan; 27(1):166-74. PubMed ID: 9425933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease.
    Colombo C; Crosignani A; Alicandro G; Zhang W; Biffi A; Motta V; Corti F; Setchell KDR
    J Pediatr; 2016 Oct; 177():59-65.e1. PubMed ID: 27297203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
    O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment.
    Chretien Y; Poupon R; Gherardt MF; Chazouilleres O; Labbe D; Myara A; Trivin F
    Gut; 1989 Aug; 30(8):1110-5. PubMed ID: 2767508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid.
    Combes B; Carithers RL; Maddrey WC; Munoz S; Garcia-Tsao G; Bonner GF; Boyer JL; Luketic VA; Shiffman ML; Peters MG; White H; Zetterman RK; Risser R; Rossi SS; Hofmann AF
    Hepatology; 1999 Jun; 29(6):1649-54. PubMed ID: 10347103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study.
    Crosignani A; Battezzati PM; Setchell KD; Camisasca M; Bertolini E; Roda A; Zuin M; Podda M
    Hepatology; 1991 Feb; 13(2):339-44. PubMed ID: 1671665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect of ursodeoxycholic acid treatment.
    Batta AK; Arora R; Salen G; Tint GS; Eskreis D; Katz S
    J Lipid Res; 1989 Dec; 30(12):1953-62. PubMed ID: 2621422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis.
    Stiehl A; Rudolph G; Raedsch R; Möller B; Hopf U; Lotterer E; Bircher J; Fölsch U; Klaus J; Endele R
    Hepatology; 1990 Sep; 12(3 Pt 1):492-7. PubMed ID: 2401455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of ursodeoxycholic acid on biliary bile acid composition in patients with cholesterol gallstone.
    Kanazawa Y; Koizumi M; Hirakawa H; Endo K; Yoshida S; Miyakawa T; Konno Y; Goto Y; Goto J; Nambara T
    Tohoku J Exp Med; 1982 Mar; 136(3):235-49. PubMed ID: 7071843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis.
    Podda M; Ghezzi C; Battezzati PM; Crosignani A; Zuin M; Roda A
    Gastroenterology; 1990 Apr; 98(4):1044-50. PubMed ID: 1968871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differing effects of nor-ursodeoxycholic or ursodeoxycholic acid on hepatic histology and bile acid metabolism in the rabbit.
    Cohen BI; Hofmann AF; Mosbach EH; Stenger RJ; Rothschild MA; Hagey LR; Yoon YB
    Gastroenterology; 1986 Jul; 91(1):189-97. PubMed ID: 3710068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration.
    Crosignani A; Podda M; Battezzati PM; Bertolini E; Zuin M; Watson D; Setchell KD
    Hepatology; 1991 Dec; 14(6):1000-7. PubMed ID: 1959845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate.
    Rudolph G; Kloeters-Plachky P; Sauer P; Stiehl A
    Eur J Clin Invest; 2002 Aug; 32(8):575-80. PubMed ID: 12190957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.
    Colombo C; Battezzati PM; Podda M; Bettinardi N; Giunta A
    Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: a randomized, placebo-controlled, crossover trial.
    Merli M; Bertasi S; Servi R; Diamanti S; Martino F; De Santis A; Goffredo F; Quattrucci S; Antonelli M; Angelico M
    J Pediatr Gastroenterol Nutr; 1994 Aug; 19(2):198-203. PubMed ID: 7815243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis.
    Smith JL; Lewindon PJ; Hoskins AC; Pereira TN; Setchell KD; O'Connell NC; Shepherd RW; Ramm GA
    Hepatology; 2004 Jun; 39(6):1673-82. PubMed ID: 15185309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.